Integration of breast-oncology clinical pathways in Providence Southern California clinical research network.

Parvin F. Peddi Saint John’s Cancer Institute, Santa Monica, CA info_outline Parvin F. Peddi, Thomas Bott, Nanor Bozoyan, Trisha Babcock, Kristen Cushman, Santosh Kesari

Authors Parvin F. Peddi Saint John’s Cancer Institute, Santa Monica, CA info_outline Parvin F. Peddi, Thomas Bott, Nanor Bozoyan, Trisha Babcock, Kristen Cushman, Santosh Kesari Organizations Saint John’s Cancer Institute, Santa Monica, CA, Providence California Regional Services, Irvine, CA, Providence Health and Services, Renton, WA, Elsevier, Park City, UT, Elsevier, Salt Lake City, UT, Pacific Neuroscience Institute, Providence Saint John’s Health Center, Santa Monica, CA Abstract Disclosures Research Funding No funding received None. Background: ClinicalPath is an evidence-based oncology decision support and analytics tool for cancer care. ClinicalPath’s treatment recommendations are prioritized based on efficacy, toxicity, and cost by a nationwide committee of oncologists. The pathways are updated quarterly and are expected to speed the integration of new treatments into practice, standardize therapy, improve quality, and decrease cost. The pathway system also allows for local clinical trial mapping to promote clinical trial awareness and increase enrollment. ClinicalPath provides clinical pathways delivering personalized, evidence-based oncology guidance at the point of care. ClinicalPath’s network in North America serves more than 2,000 cancer physicians, within 54 practices in 31 states (15 academic medical centers, 29 hospital systems, and 9 community practices). Methods: Providence’s Population: Our population is derived from multiple hospitals in Southern California within the Providence Health System. Methodology: Medical oncologists and Advanced Practice Providers received training on ClinicalPath before go-live. ClinicalPath was integrated into the Epic EHR in multiple Southern CA hospitals in a single month. Results: After 4 months of utilization within our Southern California region, 342 treatment decisions were made across all cancers, and 85.1% of cancer patients were treated on pathway. Of which, 103 treatment decisions were made within the breast-oncology specialty, and 93.2% of those cancer patients were treated on pathway. Conclusions: We successfully integrated and initiated ClinicalPath in a multiple hospital-affiliated community oncology clinical trial network. We are actively working across our Southern California Region to map locally available clinical trials to promote awareness and increase enrollment. Provider utilization and patient on-pathway rates are actively monitored.